The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

Metadata

Authors/Creators:	McCarthy, EM Sutton, E Nesbit, S Parker, B Jayne, D Griffiths, B Isenberg, DA Rahman, A Gordon, C D’Cruz, DP Rhodes, B Lanyon, P Vital, EM https://orcid.org/0000-0003-1637-4755 Yee, C-S Edwards, CJ Teh, L-S Akil, M McHugh, NJ Zoma, A Bruce, IN British Isles Lupus Assessment Group Biologics Register
Dates:	Published (online): 18 April 2017 Published: 1 June 2017
Institution:	The University of Leeds
Depositing User:	Symplectic Publications
Date Deposited:	25 Sep 2018 15:05
Last Modified:	25 Sep 2018 15:05
Status:	Published
Publisher:	Oxford University Press
Identification Number:	https://doi.org/10.1093/rheumatology/kex044

McCarthy, EM, Sutton, E, Nesbit, S, Parker, B, Jayne, D, Griffiths, B, Isenberg, DA, Rahman, A, Gordon, C, D’Cruz, DP, Rhodes, B, Lanyon, P, Vital, EM, Yee, C-S, Edwards, CJ, Teh, L-S, Akil, M, McHugh, NJ, Zoma, A, Bruce, IN and British Isles Lupus Assessment Group Biologics Register The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. (deposited 25 Sep 2018 15:05) [Currently Displayed]
- McCarthy, EM, Sutton, E, Nesbit, S, Parker, B, Jayne, D, Griffiths, B, Isenberg, DA, Rahman, A, Gordon, C, D’Cruz, DP, Rhodes, B, Lanyon, P, Vital, EM, Yee, C-S, Edwards, CJ, Teh, L-S, Akil, M, McHugh, NJ, Zoma, A, Bruce, IN and British Isles Lupus Assessment Group Biologics Register Corrigendum: The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. (deposited 25 Sep 2018 14:53)

CORE (COnnecting REpositories)